Literature DB >> 3155574

Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker.

M K Waldor, S Sriram, R Hardy, L A Herzenberg, L A Herzenberg, L Lanier, M Lim, L Steinman.   

Abstract

Administration of a monoclonal antibody (GK1.5) that recognizes the L3T4 marker present on helper T cells prevented the development of experimental allergic encephalomyelitis (EAE) in mice. Furthermore, treatment with GK1.5 reversed EAE when the antibody was given to paralyzed animals. In vivo injection of GK1.5 selectively reduced the number of L3T4+ cells in the spleen and the lymph nodes. These results suggest that manipulation of the human equivalent of the murine L3T4+ T-cell subset with monoclonal antibodies may provide effective therapy for certain autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155574     DOI: 10.1126/science.3155574

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  79 in total

1.  Preventive effects of early anti-CD4 or anti-CD8 treatment on Borna disease in rats.

Authors:  L Stitz; M Sobbe; T Bilzer
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 2.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 3.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 4.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

5.  A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Authors:  D E Smilek; D C Wraith; S Hodgkinson; S Dwivedy; L Steinman; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

Authors:  S Sriram; D J Topham; S K Huang; M Rodriguez
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

Review 7.  Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal.

Authors:  Lawrence Steinman
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

8.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis.

Authors:  H Körner; A L Goodsall; F A Lemckert; B J Scallon; J Ghrayeb; A L Ford; J D Sedgwick
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

10.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.